These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2874226)

  • 41. [The pharmacology of 1-(2-pyrimidinyl)piperazine, a metabolite of buspirone].
    Komissarov IV; Dulenko VI; Kharin NA; Tolkunov SV; Talalaenko AN
    Farmakol Toksikol; 1989; 52(2):27-30. PubMed ID: 2568272
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists.
    Meller E; Goldstein M; Bohmaker K
    Mol Pharmacol; 1990 Feb; 37(2):231-7. PubMed ID: 1968223
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Buspirone, 8-OH-DPAT and ipsapirone: effects on hippocampal cerebellar and sciatic fiber excitability.
    Hiner BC; Mauk MD; Peroutka SJ; Kocsis JD
    Brain Res; 1988 Sep; 461(1):1-9. PubMed ID: 2906267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of buspirone on sleep in the rat.
    Lerman JA; Kaitin KI; Dement WC; Peroutka SJ
    Neurosci Lett; 1986 Dec; 72(1):64-8. PubMed ID: 2880319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Buspirone hydrochloride: a unique new anxiolytic agent. Pharmacokinetics, clinical pharmacology, abuse potential and clinical efficacy.
    Goldberg HL
    Pharmacotherapy; 1984; 4(6):315-24. PubMed ID: 6151170
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of buspirone on prolactin and growth hormone secretion in laboratory rodents and man.
    Meltzer HY; Fleming R
    J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):76-9. PubMed ID: 6130077
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacology and neurochemistry of buspirone.
    Riblet LA; Taylor DP; Eison MS; Stanton HC
    J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):11-8. PubMed ID: 6130068
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and biological evaluation of 7-azaanalogues of ipsapirone.
    Malinka W; Sielklucka-Dziuba M; Rajtar G; Marowska D; Kleinrok Z
    Farmaco; 1995 Nov; 50(11):769-78. PubMed ID: 8593174
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of buspirone on operant behavior of laboratory rats and cynomolgus monkeys.
    Geller I; Hartmann RJ
    J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):25-33. PubMed ID: 6130070
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological and clinical effects of buspirone.
    Taylor DP; Eison MS; Riblet LA; Vandermaelen CP
    Pharmacol Biochem Behav; 1985 Oct; 23(4):687-94. PubMed ID: 2866549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of 5-HT1A receptors in the ability of mixed 5-HT1A receptor agonist/dopamine D2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats.
    Kleven M; Prinssen EP; Koek W
    Eur J Pharmacol; 1996 Oct; 313(1-2):25-34. PubMed ID: 8905325
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurophysiological effects of buspirone and isapirone in the hippocampus: comparison with 5-hydroxytryptamine.
    Rowan MJ; Anwyl R
    Eur J Pharmacol; 1986 Dec; 132(1):93-6. PubMed ID: 2880731
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
    Jurczyk S; Kołaczkowski M; Maryniak E; Zajdel P; Pawłowski M; Tatarczyńska E; Kłodzińska A; Chojnacka-Wójcik E; Bojarski AJ; Charakchieva-Minol S; Duszyńska B; Nowak G; Maciag D
    J Med Chem; 2004 May; 47(10):2659-66. PubMed ID: 15115407
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 5-HT1A receptor agonist effects of BMY-14802 on serotonin release in dorsal raphe and hippocampus.
    Matos FF; Korpinen C; Yocca FD
    Eur J Pharmacol; 1996 Dec; 317(1):49-54. PubMed ID: 8982718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Profile of action of a novel 5-hydroxytryptamine1A receptor ligand E-4424 to inhibit aversive behavior in the mouse, rat and marmoset.
    Costall B; Domeney AM; Farre AJ; Kelly ME; Martinez L; Naylor RJ
    J Pharmacol Exp Ther; 1992 Jul; 262(1):90-8. PubMed ID: 1352556
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes in rat brain monoamine turnover following chronic antidepressant administration.
    Sugrue MF
    Life Sci; 1980 Feb; 26(6):423-9. PubMed ID: 6154860
    [No Abstract]   [Full Text] [Related]  

  • 57. Levels of HVA and DOPAC in mouse corpus striatum in the supersensitivity phase after neuroleptic treatment.
    Hyttel J
    J Neurochem; 1977 Jan; 28(1):227-8. PubMed ID: 833596
    [No Abstract]   [Full Text] [Related]  

  • 58. Buspirone, a non-benzodiazepine anxiolytic, increases locus coeruleus noradrenergic neuronal activity.
    Sanghera MK; McMillen BA; German DC
    Eur J Pharmacol; 1982 Dec; 86(1):107-10. PubMed ID: 6130954
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Buspirone: review of its pharmacology and current perspectives on its mechanism of action.
    Eison AS; Temple DL
    Am J Med; 1986 Mar; 80(3B):1-9. PubMed ID: 2870639
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of BMY 14802, a potential antipsychotic drug, on rat brain dopaminergic function.
    Matthews RT; McMillen BA; Sallis R; Blair D
    J Pharmacol Exp Ther; 1986 Oct; 239(1):124-31. PubMed ID: 2876091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.